Roger S McIntyre

Roger S McIntyre, MD, FRCPC

Dr. Roger McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and the Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada.

Dr. McIntyre was named by Thomson Reuters in 2014 as one of “The World’s Most Influential Scientific Minds”. This distinction is bestowed upon researchers who publish the most highly cited articles in a variety of scientific fields during the previous decade.

Dr. McIntyre is extensively involved in medical education.  He is a highly sought-after speaker at both national and international meetings. He has received several teaching awards from the University of Toronto’s Department of Psychiatry and has been selected for the joint Canadian Psychiatric Association (CPA)/Council of Psychiatric Continuing Education Award for the Most Outstanding Continuing Education Activity in Psychiatry in Canada.
 
Dr. McIntyre is the co-chair of the Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force on the Treatment of Comorbidity in Adults with Major Depressive Disorder or Bipolar Disorder and as well a contributor to the CANMAT guidelines for the treatment of Depressive Disorders and Bipolar Disorders. Dr. McIntyre has published hundreds of peer-reviewed articles and has edited and/or co-edited several textbooks on mood disorders.

Dr. McIntyre completed his medical degree at Dalhousie University and completed his Psychiatry residency training and Fellowship in Psychiatric Pharmacology at the University of Toronto.
Dr. McIntyre is involved in multiple research endeavours which aim to characterize the association between mood disorders, especially cognitive function and medical comorbidity.  Broadly, his work aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment.
Psychother Psychosom. 2016 Nov 25;86(1):31-46
Slyepchenko A, Maes M, Jacka FN, Köhler CA, Barichello T, McIntyre RS, Berk M, Grande I, Foster JA, Vieta E, Carvalho AF
Neurosci Biobehav Rev. 2016 Nov 18;:
Yamagata AS, Mansur RB, Rizzo LB, Rosenstock T, McIntyre RS, Brietzke E
Int Clin Psychopharmacol. 2016 Nov 16;
Wesnes KA, Gommoll C, Chen C, Sambunaris A, McIntyre RS, Harvey PD
Prim Care Companion CNS Disord. 2016 Sep 1;18(5):
Habert J, Katzman MA, Oluboka OJ, McIntyre RS, McIntosh D, MacQueen GM, Khullar A, Milev RV, Kjernisted KD, Chokka PR, Kennedy SH
J Affect Disord. 2016 Oct 24;:
Lee JH, Park SK, Ryoo JH, Oh CM, Mansur RB, Alfonsi JE, Cha DS, Lee Y, McIntyre RS, Jung JY
J Clin Psychiatry. 2016 Oct;77(10):e1355
McIntyre RS
Oncotarget. 2016 Oct 23;:
Chen VC, Lin CF, Hsieh YH, Liang HY, Huang KY, Chiu WC, Lee Y, McIntyre RS, Chan HL
J Clin Psychiatry. 2016 Oct 25;:
McIntyre RS, Florea I, Tonnoir B, Loft H, Lam RW, Christensen MC
J Affect Disord. 2016 Oct 1;207:353-358
Lee HC, Chiu WC, Wang TN, Liao YT, Chien IC, Lee Y, McIntyre RS, Chen PC, Chen VC
J Affect Disord. 2016 Oct 1;207:114-120
Mansur RB, Ahmed J, Cha DS, Woldeyohannes HO, Subramaniapillai M, Lovshin J, Lee JG, Lee JH, Brietzke E, Reininghaus EZ, Sim K, Vinberg M, Rasgon N, Hajek T, McIntyre RS

Pages


 

Head, Mood Disorders Psychopharmacology Unit, UHN
Professor, Departments of Psychiatry and Pharmacology and Toxicology, University of Toronto